Vector purification is the process of separating one or more substances from contaminants that accompany them during isolation from nature or production. Vectors are the most important component required for the delivery of therapeutic genes in various gene therapy and gene editing applications. The rising demand for gene therapies to treat various diseases such as cancer, genetic disorders, infectious diseases and others is expected to boost the growth of the vector purification market. The conventional techniques for vector purification include cesium chloride density gradient ultracentrifugation, size-exclusion chromatography and affinity chromatography. However, modern techniques such as tangential flow filtration and chromatographic techniques are gaining traction in the industry due to advantages such as scalability, high yield and reduced purification time.
The vector purification market is estimated to be valued at USD 336 Mn in 2024 and is expected to reach USD 1,300 Mn by 2031, growing at a compound annual growth rate (CAGR) of 21.3% from 2024 to 2031.
Key Takeaways
- Key players operating in the vector purification market are Merck KGaA, Agilent Technologies Inc., Danaher, Thermo Fisher Scientific, General Electric, Nexelis, Lonza and Taiyo Nippon Sanso Corporation.
- Increasing demand for gene and cell therapies for treatment of Vector Purification Market is expected to drive the growth of vector purification market. Gene therapies in clinical trials or approved for conditions like retinal dystrophy, leukemia, skin cancer, hemophilia and others require large-scale production of viral vectors.
- Advancements in chromatographic and filtration techniques have enabled higher vector yields and purity in lesser time. Technologies like expanded bed adsorption chromatography, simulated moving bed chromatography and tangential flow filtration aid scalable and robust vector purification processes.
Market Trends
- Continuous processing is gaining attention to enable integrated and automated operations for vector purification. Technologies like periodic counter current chromatography allow running purification steps without interruption for higher productivity.
- Designer scaffolds are being explored to develop affinity ligands with improved selectivity and batch-to-batch consistency. Novel materials such as nanoparticles, aptamers and camelid antibodies can enable robust capture step optimization.
Market Opportunities
- Growth in AAV gene therapy clinical trials for diseases like neurological disorders, muscle and pulmonary conditions will boost commercial-scale vector manufacturing and purification needs.
- Developing economies in Asia Pacific andLatin America experiencing rise in gene therapy research and investments will present new geographic markets for vector purification solution and service providers.
Impact of Covid-19 on Vector Purification Market Growth
The Covid-19 pandemic has significantly impacted the vector purification market. In the initial months of the pandemic, most research activities came to a halt as lockdowns were imposed globally. This led to a steep decline in demand for vector purification products from research institutes and pharmaceutical companies. Suppliers also faced disruptions in their supply chains and manufacturing facilities. However, as the pandemic intensified and vaccine development became the top priority, demand started increasing rapidly. Many biotech companies and research labs ramped up their development of viral vector-based vaccines and therapeutics for Covid-19. This surge in R&D activities for viral vector technologies bolstered the sales of vector purification systems, kits, resins and other products. Going forward, vaccine production and development of more effective treatments against variants will remain key growth drivers. Manufacturers are enhancing their production capacities to cater to the exponential rise in requirements. The pandemic has accelerated the expansion of this market and highlighted the importance of vector purification in vaccine innovation.
Major geographical regions with concentration in vector purification market value
North America dominates the global vector purification market, primarily due to heavy investments by research institutes and biopharma companies in the US and Canada. Presence of many leading vaccine manufacturers and favorable government funding for life science R&D keeps North America at the forefront. Europe is another major regional market, powered by robust biotech industries in Germany, UK, France and other developed nations. Countries like China, India and South Korea are fast-emerging as high-potential markets in the Asia Pacific region due to low-cost manufacturing advantages and increasing government support for healthcare sector growth. Besides developed markets, developing economies will continue contributing significantly to the rising global demand.
Fastest growing region for vector purification market
Asia Pacific region is projected to witness the highest growth in the vector purification market during the forecast period. Factors such as rapid economic development, increasing healthcare spending, rising prevalence of diseases, growing outsourcing of clinical research to Asia, and strengthening biopharmaceutical industry in China and India are driving the demand. Moreover, supportive government initiatives, emergence of local manufacturers, and higher willingness of biotechs to invest in Asia Pacific will further propel the market expansion over the coming years. Significant upcoming opportunities in vaccine production and gene & cell therapy research will aid Asia Pacific to achieve the fastest CAGR in the global vector purification landscape.
Get more insights on — Vector Purification Market
Get this Report in Japanese Language: ベクター精製市場
Get this Report in Korean Language: 벡터 정제 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
